Business & Industry

Eli Lilly has agreed to acquire in vivo CAR-T developer Orna Therapeutics in a deal worth up to $2.4 billion, marking another rapid move to strengthen its research pipeline. The transaction positions Lilly buys Orna for $2.4bn as a...

Innovent Biologics has announced a strategic Innovent-Lilly partnership with Eli Lilly and Company to advance the global development of new medicines in oncology and immunology. The agreement represents the seventh partnership between the two companies and introduces a new...

Deep dive into the convergence of medical engineering and pharmaceutical science, focusing on how integrated delivery systems enhance dosing accuracy and patient outcomes.

GSK’s new chief executive, Luke Miels, said the drugmaker will prioritise faster drug development as it enters its next phase of growth, with a tighter focus on programmes that can change standards of care and selective bolt-on acquisitions. Miels,...

Examination of the pharmaceutical industry's transition toward biodegradable polymers and eco-friendly excipients to reduce environmental impact while maintaining high therapeutic standards.

The UK and Japanese governments have announced a wide-ranging partnership that sees UK and Japan strengthen science and technology ties across pharmaceuticals, genomics, quantum computing and advanced manufacturing. The agreement was confirmed during a visit to Japan by the...

Halo Pharma becomes dedicated North American drug product CDMO after emerging as a standalone contract development and manufacturing organization focused exclusively on drug product services in North America. The transition follows SK Capital Partners’ decision to divest the active...